Jazz Pharmaceuticals PLC $JAZZ Stock Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 50.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 76,421 shares of the specialty pharmaceutical company’s stock after acquiring an additional 25,671 shares during the period. Russell Investments Group Ltd.’s holdings in Jazz Pharmaceuticals were worth $17,696,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Castleark Management LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $9,214,000. SEB Asset Management AB bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth about $8,765,000. Bank of America Corp DE lifted its stake in shares of Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. California Public Employees Retirement System lifted its stake in shares of Jazz Pharmaceuticals by 10.6% in the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after purchasing an additional 11,915 shares during the period. Finally, Angeles Wealth Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $1,221,000. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on JAZZ shares. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, November 9th. Barclays boosted their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. Royal Bank Of Canada increased their price target on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the stock an “outperform” rating in a report on Tuesday, November 3rd. Truist Financial increased their price target on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Finally, Deutsche Bank raised their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $294.25.

Read Our Latest Report on JAZZ

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the transaction, the executive vice president owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 68,808 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the completion of the transaction, the director directly owned 357,567 shares of the company’s stock, valued at approximately $84,367,933.65. This trade represents a 16.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 171,342 shares of company stock valued at $41,420,491. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $247.77 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $156.95 and a 52 week high of $266.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The business has a 50 day moving average price of $229.13 and a 200-day moving average price of $220.79. The company has a market cap of $15.90 billion, a PE ratio of 21.34, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the firm earned $8.13 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.18 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Further Reading

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.